National Drug and Alcohol Research Centre, University of New South Wales Sydney, Sydney, NSW, Australia.
Kirby Institute, University of New South Wales Sydney, Sydney, NSW, Australia.
Lancet. 2019 Oct 26;394(10208):1560-1579. doi: 10.1016/S0140-6736(19)32229-9. Epub 2019 Oct 23.
We summarise the evidence for medicinal uses of opioids, harms related to the extramedical use of, and dependence on, these drugs, and a wide range of interventions used to address these harms. The Global Burden of Diseases, Injuries, and Risk Factors Study estimated that in 2017, 40·5 million people were dependent on opioids (95% uncertainty interval 34·3-47·9 million) and 109 500 people (105 800-113 600) died from opioid overdose. Opioid agonist treatment (OAT) can be highly effective in reducing illicit opioid use and improving multiple health and social outcomes-eg, by reducing overall mortality and key causes of death, including overdose, suicide, HIV, hepatitis C virus, and other injuries. Mathematical modelling suggests that scaling up the use of OAT and retaining people in treatment, including in prison, could avert a median of 7·7% of deaths in Kentucky, 10·7% in Kiev, and 25·9% in Tehran over 20 years (compared with no OAT), with the greater effects in Tehran and Kiev being due to reductions in HIV mortality, given the higher prevalence of HIV among people who inject drugs in those settings. Other interventions have varied evidence for effectiveness and patient acceptability, and typically affect a narrower set of outcomes than OAT does. Other effective interventions focus on preventing harm related to opioids. Despite strong evidence for the effectiveness of a range of interventions to improve the health and wellbeing of people who are dependent on opioids, coverage is low, even in high-income countries. Treatment quality might be less than desirable, and considerable harm might be caused to individuals, society, and the economy by the criminalisation of extramedical opioid use and dependence. Alternative policy frameworks are recommended that adopt an approach based on human rights and public health, do not make drug use a criminal behaviour, and seek to reduce drug-related harm at the population level.
我们总结了阿片类药物的药用用途、与这些药物的非医疗使用和依赖相关的危害,以及用于解决这些危害的广泛干预措施。全球疾病、伤害和风险因素研究估计,2017 年有 4050 万人依赖阿片类药物(95%不确定区间为 3430 万至 4790 万),有 109500 人(105800 至 113600)死于阿片类药物过量。阿片类药物激动剂治疗(OAT)可以非常有效地减少非法使用阿片类药物,并改善多种健康和社会结果,例如,降低总死亡率和关键死因,包括过量、自杀、艾滋病毒、丙型肝炎病毒和其他伤害。数学模型表明,扩大 OAT 的使用并使包括在监狱中的患者继续接受治疗,可以在肯塔基州预防中位数 7.7%的死亡,在基辅预防 10.7%的死亡,在德黑兰预防 25.9%的死亡(与没有 OAT 相比),在德黑兰和基辅的效果更大,这是因为艾滋病毒死亡率降低,因为在这些地区注射毒品的人中艾滋病毒的流行率更高。其他干预措施对有效性和患者接受度的证据各不相同,并且通常对 OAT 的影响范围更窄。其他有效的干预措施侧重于预防与阿片类药物相关的伤害。尽管有强有力的证据表明,一系列改善依赖阿片类药物的人的健康和福祉的干预措施有效,但覆盖率仍然很低,即使在高收入国家也是如此。治疗质量可能不如人意,并且将非医疗使用和依赖阿片类药物定为犯罪可能会给个人、社会和经济造成相当大的伤害。建议采用基于人权和公共卫生的替代政策框架,不要将吸毒行为定为犯罪行为,并寻求在人群层面减少与毒品有关的伤害。